Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

Table 3 Individual-level association between real-world progression-free survival and overall survival in metastatic breast cancer (mBC) patients after diagnosis of mBC, according to mBC subtype

	Patients	ρ coef	95% CI
TN
Chemotherapy only	1804	0.81	0.79 − 0.82
Chemotherapy and targeted therapy	921	0.73	0.69 − 0.76
HR + /HER2 +
Chemotherapy only	84	0.33	0.12 − 0.52
Endocrine therapy only	342	0.43	0.32 − 0.53
Chemotherapy and endocrine therapy	85	0.72	0.58 − 0.82
Chemotherapy and targeted therapy	674	0.67	0.61 − 0.72
Chemotherapy, targeted therapy, and endocrine therapy	1036	0.78	0.74 − 0.82
Endocrine therapy and targeted therapy	228	0.71	0.61 − 0.78
HR − /HER2 +
Chemotherapy only	75	0.67	0.51 − 0.78
Chemotherapy and targeted therapy	1164	0.81	0.78 − 0.84
HR + /HER2 −
Chemotherapy only	1631	0.58	0.54 − 0.61
Endocrine therapy only	5545	0.66	0.64 − 0.68
Chemotherapy and endocrine therapy	3383	0.78	0.76 − 0.79
Chemotherapy and targeted therapy	699	0.45	0.39 − 0.51
Chemotherapy, targeted therapy and endocrine therapy	1518	0.70	0.67 − 0.73
Endocrine therapy and targeted therapy	492	0.61	0.51 − 0.70

Abbreviations: mBC, metastatic breast cancer; HR + , presence of hormone receptor; HR − , absence of hormone receptor; HER2 + , human epidermal growth factor receptor 2 (HER2) protein overexpression; HER2 − , no HER2 protein overexpression; TN, triple negative
Correlations are expressed as Spearman’s ρ coefficient with 95% confidence interval (95% CI)

ISSN: 1741-7015